Based on prior preclinical data demonstrating that EGFR inhibitors can sensitize non-BRCA tumors to PARP inhibitors and lead to an increase in tumor cell death in TNBC models, we performed an open-label pilot study of lapatinib and veliparib combination therapy in patients with refractory TNBC without a BRCA1/2 alteration. Here, EGFR is linked to neoplasm.